Sapir Venture Partners
Sapir Venture Partners is a micro-venture capital firm established in 2015, based in Jerusalem, Israel. The firm specializes in pre-seed stage investments, primarily targeting innovative startups founded by Israeli entrepreneurs in regions such as Boston, New York, and Israel. Sapir Venture Partners focuses on leveraging cutting-edge science and deep technologies to foster positive societal impacts. In addition to providing financial support, the firm offers mentorship to help founders navigate the challenges of early-stage development, emphasizing sectors such as materials and resources, healthcare, energy, and information technology.
DeepCure Inc. specializes in drug discovery services powered by artificial intelligence. The company employs advanced algorithms for De-novo Lead Discovery, which analyzes drug candidates from a virtual library, and utilizes AI-driven Lead Optimization to enhance drug development processes. Additionally, DeepCure's proprietary database, MoIDB, is designed to maximize the scale, diversity, and synthesizability of the chemical search space. Founded in 2018 and based in Boston, Massachusetts, DeepCure aims to accelerate the development of innovative, first-in-class precision therapeutics that address unmet medical needs. The company combines deep learning algorithms with cloud computing to improve pre-clinical drug development, ultimately assisting scientists and healthcare professionals in creating more effective therapeutic molecules for various disease targets.
DeepCure
Pre Seed Round in 2018
DeepCure Inc. specializes in drug discovery services powered by artificial intelligence. The company employs advanced algorithms for De-novo Lead Discovery, which analyzes drug candidates from a virtual library, and utilizes AI-driven Lead Optimization to enhance drug development processes. Additionally, DeepCure's proprietary database, MoIDB, is designed to maximize the scale, diversity, and synthesizability of the chemical search space. Founded in 2018 and based in Boston, Massachusetts, DeepCure aims to accelerate the development of innovative, first-in-class precision therapeutics that address unmet medical needs. The company combines deep learning algorithms with cloud computing to improve pre-clinical drug development, ultimately assisting scientists and healthcare professionals in creating more effective therapeutic molecules for various disease targets.
ConsortiaTX,
Pre Seed Round in 2018
ConsortiaTX, Inc. is a seed stage, pre-clinical bio-therapeutics company that emerged from research laboratories at Brigham & Women’s Hospital and Children’s Hospital in Boston. The company’s intellectual property around food allergies and the human gut microbiome is based on the work of Lynn Bry, M.D., Ph.D., Georg Gerber, M.D., Ph.D. (both at BWH), and Talal Chatilla, Ph.D. (at CHB) and others.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.